Últimos Artículos de Terapeuthic Advances in Endocrinology and Metabolism
- Erratum to “Unrecognized primary aldosteronism may confound outcomes in adrenal Cushing’s syndrome”
- Serum testosterone and uric acid: Key biomarkers for predicting response to drospirenone/ethinyl estradiol tablets (II) in adolescents polycystic ovary syndrome
- Author’s reply to the letter to the editor by Yongzhang Qin and Shihua Hong, “Unrecognized primary aldosteronism may confound outcomes in adrenal Cushing’s syndrome”
- Impact of training type (virtual vs in-person) on long-term glycemic control in people with type 1 diabetes using minimed 780: A non-inferiority longitudinal study
- Metabolic effects of GLP-1 and GLP-2 across fed, fasting, and starvation states: A systematic review with structured narrative synthesis
- Systematic review and network meta-analysis of the safety and efficacy of the triple incretin receptor agonist, retatrutide compared to the dual incretin receptor agonist, tirzepatide, for treatment of type 2 diabetes mellitus
- The uric acid-to-homocysteine ratio as a prognostic marker for all-cause and cardiovascular mortality: A national population-based study
- Associations of mortality and sepsis after GLP-1 receptor agonist initiation versus SGLT2 inhibitor or metformin initiation in people with HIV, overweight or obesity, and type 2 diabetes: A target trial emulation
- Dietary protein content and its impact on amino acid profile and appetite in patients with methylmalonic acidemia
- Hashimoto’s thyroiditis and ablation-zone involution after microwave ablation for low-risk papillary thyroid carcinoma: An overlap-weighted cohort study
- Association between the ratio of uric acid to high-density lipoprotein cholesterol (UHR) and the abnormal risk of sarcopenia: Evidence from two large population-based surveys and interpretable machine learning-driven sarcopenia screening
- Association between HOMA-IR and coexisting MASLD and type 2 diabetes: Insights from NHANES and network pharmacology
- Association between glycerol triglyceride glucose-related index and cardiovascular disease in individuals with metabolic dysfunction-associated steatotic liver disease: NHANES 1999–2023
- A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of vosoritide in children with hypochondroplasia: CANOPY HCH-3 study design
- GLP-1 receptor agonists at the crossroads of metabolic and gut inflammation: Implications for people with type 2 diabetes and inflammatory bowel disease
- Teplizumab in stage 2 type 1 diabetes- pediatric considerations, realistic expectations, and the evolving technological landscape
- Unrecognized primary aldosteronism may confound outcomes in adrenal Cushing’s syndrome
- From traditional to novel: a national cohort study on the predictive value of C-reactive protein–triglyceride–glucose-obesity composite parameters for cardiovascular disease
- Facilitators, barriers, and interventions for exercise adherence in patients with prediabetes: a mixed-methods systematic review
- Beyond glycemic control: clinical cardiovascular effects of tirzepatide—a narrative review